We work with the prediction of pharmacokinetics of new targeted treatments (eg erlotinib and dabrafenib) and side effects of classical chemotherapy especially in the treatment of lung cancer (gemcitabine and carboplatin), ovarian and breast cancer (paclitaxel / docetaxel and carboplatin) and pancreatic cancer (Nab-paclitaxel and gemcitabine).
Individualized cancer treatment
